Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 27.5% in December

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 5,000 shares, a decline of 27.5% from the November 30th total of 6,900 shares. Based on an average daily trading volume, of 8,100 shares, the short-interest ratio is currently 0.6 days.

Clinuvel Pharmaceuticals Trading Up 0.8 %

OTCMKTS:CLVLY traded up $0.07 during mid-day trading on Friday, hitting $7.88. The stock had a trading volume of 539 shares, compared to its average volume of 2,853. Clinuvel Pharmaceuticals has a twelve month low of $7.46 and a twelve month high of $11.43. The company’s 50 day simple moving average is $8.58 and its 200 day simple moving average is $9.36.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).